

Inpatient care of people who inject drugs admitted with invasive infections: A retrospective review to inform a model of care


Dr Yael Hammerschlag
Infectious diseases & Addiction medicine trainee
Naarm, Melbourne




I, Yael Hammerschlag, have no conflicts of interest to disclose.

What is the problem?


Rising rates of IRI




Complicated treatments



Differing priorities



Methods



Recommendations

Addiction medicine review
Pain review
OAT
Flexible antibiotic plans



Patient database 2019-2021

Large tertiary healthcare service
Kept by Addiction Medicine Unit



Reviewed records

Do we provide best practice care?



Participants N=74

49 (66%) Male



42 years (36-48)

11 (15%) Alcohol use



7 (9.5%) Chronic pain

38 (51%) Psych diagnosis

50 (68%) Opioids



44 (59%) Methamphetamine

**17 (23%) Opioids &
methamphetamine**

59 (80%) nicotine

40 (54%) OAT




26 Methadone

9 Sublingual buprenorphine


5 LAIB

Outcomes



24 (32%)

Endocarditis




17 (23%)

Early addiction review

18 (24%)

Pain review



12 (16%)

Received education

0

Take home naloxone

26 (35%)

Patient-directed discharge

32 (43%)

Completed therapy

24 (32%)

Attended follow up

Recommendations

Flexible models of care

Community partnerships

Early addiction medicine review

Preventative healthcare



Acknowledgements

Supervisors

Dr Lucy Attwood

Professor Allen Cheng

